Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 52, n° 3S
page P1 (mars 2005)
Doi : 10.1016/j.jaad.2004.10.019
Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis

Paul Yamauchi, MD, PhD, Nicolas Lowe, MD, Clinical Research Specialists, Santa Monica, CA, United States; Supin Koo, PhD, Amgen, Thousand Oaks, CA, United States

Dr. Yamauchi is a consultant, principal investigator, and speaker for Amgen but has no proprietary interest in the company. Dr. Lowe is a member of the Speakers Bureau for Amgen. Dr. Koo is an employee of Amgen.
Writing support and poster production provided by Immunex Corporation, a wholly owned subsidiary of Amgen Inc., and by Wyeth Research.

Top of the page

© 2005  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline